John Carroll

Biography for John Carroll

John D. Carroll, Editor-in-Chief

John D. Carroll is a biotech analyst with 36 years of experience in journalism that’s taken him all over the world--and back again. Appointed editor of FierceBiotech in 2003, he has covered everything from city hall in Kansas City, KS, to biotech in London. He contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and a medley of other publications. He spent six years as editor and then publisher of the Dallas Business Journal, was publisher of Texas Business for a brief stint and early in his career was part of a big team of reporters and editors at the Kansas City Star & Times that investigated the deadly 1981 disaster at a local Hyatt Regency. The newspapers won a 1982 Pulitzer for their collective work. Carroll lives in Vermont and travels frequently. He can be reached at Follow @JohnCFierce on Twitter.

Articles by John Carroll

Sanofi launches PhII study of C. diff vaccine

Sanofi Pasteur has launched an ambitious mid-stage clinical trial for an experimental new vaccine that will attempt to thwart the rising risk of hospital-acquired Clostridium difficile infection.

Bavarian Nordic reviewing partners for cancer vax

Bavarian Nordic says it has gathered between five and nine term sheets from potential partners for its experimental prostate cancer vaccine. The company's business development chief, Juergen

Personalized cancer vax helps keep patients tumor-free

Dartmouth investigators say that a personalized dendritic cell vaccine has produced a solid set of five-year survival data demonstrating its effectiveness at keeping patients cancer-free after their

Novartis and Venter team on faster vaccine development

Novartis is turning to J. Craig Venter to help blaze a development shortcut that can carve weeks off the time it takes to ramp up production of a new flu vaccine. One of the bottlenecks that appeared

Chief Justice dumps stock so he can hear vax case

Chief Justice John Roberts has sold all his Pfizer stock, in part so he can participate in a case that will determine if vaccine makers are guarded against certain liability suits by the federal

HHS chief promises cell-based flu vax in 2011

HHS Secretary Kathleen Sebelius says that the agency's $487 million contract with Novartis is helping spur development of a new cell-based flu vaccine that is scheduled to be on the market in time

Vax experts discuss trials, tribulations of malaria R&D

Stephen Hoffman joined a group of vaccine development experts gathering in Washington this week to discuss their progress on a new malaria jab. But the founder of Sanaria reportedly found himself on

HIV vaccine researchers ponder new strategies, drop in funding

Emboldened by a glimpse of the potential of a new HIV vaccine, more than 1,000 researchers from around the world are gathering in Atlanta this week to share their thoughts on the best strategies for

FDA warns on possible safety issue with GSK's Rotarix

The FDA has raised a red safety flag on GlaxoSmithKline's rotavirus vaccine Rotarix. The agency is reporting that preliminary data from a new study indicates that the vaccine could raise the risk of

Breast cancer vax could protect women from their 40s

Cleveland Clinic star investigator Dr. Vincent Tuohy is scouting for $16 million to help fund human trials of an experimental breast cancer vaccine designed to stop cancer from ever developing as a